1187595-90-9Relevant articles and documents
Preparation of baricitinib and derivative thereof
-
Paragraph 0028-0030, (2021/10/11)
The invention relates to synthesis of baricitinib and a derivative thereof. Specifically, (4-(1, 3-dioxolane-2-yl)-7-substituted-7H-pyrrolo [2, 3-d] pyrimidine reacts with 2-(1-(ethylsulfonyl)-3-hydrazino azetidin-3-yl) acetonitrile and (chloromethylene) dimethyl ammonium chloride in the presence of a solvent to obtain a compound 2-(1-(ethylsulfonyl)-3-(4-(7-substituted-7H-pyrrolo [2, 3-d] pyrimidine-4-yl)-1H-pyrazol-1-yl) azetidin-3-yl) acetonitrile.
BARICITINIB INTERMEDIATE, METHOD FOR FORMING BARICITINIB INTERMEDIATE, AND METHOD FOR PREPARING BARICITINIB OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
-
, (2019/07/15)
The present disclosure provides a Baricitinib intermediate, a method for preparing the Baricitinib intermediate, and a method for preparing Baricitinib or a pharmaceutically acceptable salt thereof using the Baricitinib intermediate. The method for preparing the Baricitinib intermediate involves the use of a divalent palladium catalyst or a nickel catalyst and provides the Baricitinib intermediate in high yield.
AZETIDINE AND CYCLOBUTANE DERIVATIVES AS JAK INHIBITORS
-
Page/Page column 68-69, (2009/09/28)
The present invention relates to azetidine and cyclobutane derivatives, as well as their compositions, methods of use, and processes for preparation, which are JAK inhibitors useful in the treatment of JAK-associated diseases including, for example, inflammatory and autoimmune disorders, as well as cancer.